Polypharmacy in a hospitalized psychiatric population: Risk estimation and damage quantification

BMC Psychiatry

Volumn 19, Issue 1, 2019, Pages

  Carmona Huerta, J ^a,b   Castiello De Obeso, S ^b,c,d   Ramirez Palomino J ^a   Duran Gutierrez R ^a   Cardona Muller, D ^b   Grover Paez, F ^b   Fernandez Dorantes P ^a   Medina Davalos R ^a,b  

^a Instituto Jalisciense de Salud Mental   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Instituto Tecnologico y de Estudios Superiores de Occidente   (Mexico)

Author keywords

Antipsychotic; Antipsychotic prescription duplicity; Drug drug interaction; Extrapyramidal symptoms; Hospitalized psychiatric population; Pharmacological interactions; Polypharmacy; Secondary effect

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; HALOPERIDOL; HALOPERIDOL DECANOATE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEMOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INDEPENDENT VARIABLE; LABORATORY TEST; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HOSPITAL; MENTAL PATIENT; MEXICO; POLYPHARMACY; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SOCIAL ASPECT; SUBSTANCE ABUSE; ADVERSE DRUG REACTION; COMBINATION DRUG THERAPY; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; MEXICO; MIDDLE AGED; PATIENT DISCHARGE; POLYPHARMACY; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 85061978026     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-019-2056-0     Document Type: Article

References (23)

1. Sharifi H, Hasanloei M, Mahmoudi J. Polypharmacy-induced drug-drug interactions; threats to patient safety. Drug Res. 2014;64(12):633-7.
2. Tannenbaum C, Sheehan NL. Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol. 2014;7(4):533-44.
3. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: treatment and management. United Kingdom. Nice Clinical Guideline 178. 2014. guidance.nice.org.uk/cg178.
4. American Psychiatric Association. The American Psychiatric Association practice guidelines for the psychiatric evaluation of adults. Washington (DC): American psychiatric association; 2016.
5. Westaway K, Sluggett JK, Alderman C, Procter N, Roughead E. Prevalence of multiple antipsychotic use and associated adverse effects in Australians with mental illness. Int J Evid Based Healthc. 2016;14:104-12.
6. Gallego J, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138:18-28.
7. Zepeda, K. (2014) CAISAME ESTANCIA PROLONGADA. Recuperate from: https://salme.jalisco.gob.mx/1176
8. Lingiaerde O. The Udvalg for kliniske undersøgelser (UKU) Side Effect Rating Scale. Acta Psychiatr Scand Suppl. 1987;334:1-100.
9. Simpson GN. Simpson-Angus scale. Acta Psychiatr Scand. 1970. Pp. 11-19. BMC Neurol. 2005;5(1):5.
10. Barnes TR. The Barnes akathisia rating scale revisited. J Psychopharmacol. 2003;17:365-70.
11. Guy W. Abnormal involuntary movement scale, AIMS) US Department of Health Education, and welfare, 1976.
12. Babor TF. Alcohol, Smoking and substance involvement screening test. Addiction. 97:1183-94.
13. Andreasen N, Pressler M, Nopoulos P, Miller D, Beng-Choon H. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67(3):255-62.
14. O.M.S. CIE-10. Trastornos Mentales y del Comportamiento. Décima Revisión de la Clasificación Internacional de las Enfermedades. In: Descripciones Clínicas y pautas para el diagnóstico. Ginebra: Organización Mundial de la Salud; 1992.
15. O.M.S. CIE-10. Décima Revisión de la Clasificación Internacional de las Enfermedades. In: Descripciones Clínicas y pautas para el diagnóstico. Ginebra: Organización Mundial de la Salud; 1992.
16. Kutner, M. H., Nachtsheim, C. J., & Neter, J. (2004). Applied Linear Regression Models (4th ed.). McGraw-Hill Irwin.23. Sheather, & Simon (2009). A modern approach to regression with R. New York, NY: Springer.
17. R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL: https://www.R-project.org/. Accessed 1 June 2018.
18. Encuesta nacional de adicciones de México 2011 Recuperate from: https://encuestas.insp.mx/ena/ena2011.php. Accessed 1 June 2018.
19. Encuesta Nacional de Consumo de Drogas, Alcohol y Tabaco 2016-2017. Recuperate from: https://encuestas.insp.mx/ena/encodat2017.php. Accessed 1 June 2018.
20. Lung SLM, Lee HME, Chen YHE, Chan KWS, Chang WC, Hui LMC. Prevalence and correlates of antipsychotic polypharmacy in Hong Kong. Asian J Psychiatr. 2018;33:113-20.
21. Yang SY, Chen LY, Najoan E. Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: fourth survey of research on Asian prescription patterns on antipsychotics. Psychiatry Clin Neurosci. 2018;72(8):572-9.
22. Baker J, Aebi C. Comparison of readmission data between different categories of antipsychotic drugs at a state psychiatric hospital in Oregon. Ment Health Clin. 2017;7(3):124-30.
23. Ortiz-Orendain, J., Castiello-de Obeso, S., Colunga-Lozano, L. E., Hu, Y., Maayan, N., Adams, C.E. (2017). Antipsychotic combinations for schizophrenia. The Cochrane Database Syst Rev.